
The Covid-19 pandemic and the world-spanning battle against it have delayed the California studies in which Danish diagnostics company Bioporto has been testing a quick saliva test for coronavirus, which people would ideally be able to bring home with them.
The firm's CEO Peter Mørch Eriksen still patiently awaits the results from the trials, but he won't factor in any potential revenue from the test in Bioporto's predicted fiscal year until he sees the results.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app